- Report
- May 2024
- 240 Pages
Global
From €4740EUR$4,799USD£3,944GBP
- Report
- December 2023
- 149 Pages
Global
From €4889EUR$4,950USD£4,068GBP
- Report
- December 2023
Global
From €4889EUR$4,950USD£4,068GBP
- Report
- November 2024
- 193 Pages
Global
From €3501EUR$3,545USD£2,913GBP
€3890EUR$3,939USD£3,237GBP
- Report
- October 2024
- 199 Pages
Global
From €3501EUR$3,545USD£2,913GBP
€3890EUR$3,939USD£3,237GBP
- Report
- October 2024
- 181 Pages
Global
From €3501EUR$3,545USD£2,913GBP
€3890EUR$3,939USD£3,237GBP
- Report
- October 2024
- 182 Pages
Global
From €3501EUR$3,545USD£2,913GBP
€3890EUR$3,939USD£3,237GBP
- Report
- October 2024
- 181 Pages
Global
From €3501EUR$3,545USD£2,913GBP
€3890EUR$3,939USD£3,237GBP
- Report
- October 2024
- 197 Pages
Global
From €3501EUR$3,545USD£2,913GBP
€3890EUR$3,939USD£3,237GBP
- Report
- October 2024
- 198 Pages
Global
From €3501EUR$3,545USD£2,913GBP
€3890EUR$3,939USD£3,237GBP
- Report
- October 2024
- 188 Pages
Global
From €3501EUR$3,545USD£2,913GBP
€3890EUR$3,939USD£3,237GBP
- Report
- October 2024
- 187 Pages
Global
From €3501EUR$3,545USD£2,913GBP
€3890EUR$3,939USD£3,237GBP
- Report
- October 2024
- 190 Pages
Global
From €3501EUR$3,545USD£2,913GBP
€3890EUR$3,939USD£3,237GBP
- Report
- October 2024
- 181 Pages
Global
From €3501EUR$3,545USD£2,913GBP
€3890EUR$3,939USD£3,237GBP
- Report
- October 2024
- 187 Pages
Global
From €3501EUR$3,545USD£2,913GBP
€3890EUR$3,939USD£3,237GBP
- Report
- October 2024
- 192 Pages
Global
From €3501EUR$3,545USD£2,913GBP
€3890EUR$3,939USD£3,237GBP
- Report
- October 2024
- 199 Pages
Global
From €3501EUR$3,545USD£2,913GBP
€3890EUR$3,939USD£3,237GBP
- Report
- October 2024
- 192 Pages
Global
From €3501EUR$3,545USD£2,913GBP
€3890EUR$3,939USD£3,237GBP
- Report
- June 2024
- 220 Pages
Global
From €2459EUR$2,490USD£2,046GBP
- Report
- September 2024
- 120 Pages
Global
From €5877EUR$5,950USD£4,889GBP
The Liver and Kidney Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs to treat diseases and disorders of the liver and kidneys. These drugs are used to treat a variety of conditions, including hepatitis, cirrhosis, kidney failure, and other kidney-related diseases. The market is highly competitive, with many companies vying for market share.
The market is driven by the increasing prevalence of liver and kidney diseases, as well as the development of new treatments and technologies. Additionally, the rising demand for better treatments and the increasing availability of generic drugs are also contributing to the growth of the market.
Some of the major companies in the Liver and Kidney Disorders Drugs market include Pfizer, Merck, Novartis, Sanofi, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, and AbbVie. These companies are engaged in the development and production of drugs to treat liver and kidney diseases. Show Less Read more